Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHINANEO
CTR20260613Phase 2Active
- Sponsor
- Bayer
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Apr 2026; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20260613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260613.